Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Dose Conversion of OROS Oxybutynin in Urge Urinary Incontinence
NCT00269724Phase 3Completed
- Sponsor
- ALZA Corporation
- Start
- Mar 1997
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of oxybutynin in urge urinary incontinence (UUI), sponsored by ALZA Corporation. Primary endpoints: Incidence of adverse events and Physician's Anticholinergic Effects Assessment. Started Mar 1997; status: completed.
02
Drugs
oxybutynin
03
Conditions
urge urinary incontinence (UUI)
Beyond the preview
Go deeper on NCT00269724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269724.